CD274 and neoplasm: Currently, predictive biomarkers to assess sensitivity to immunotherapy include tumor mutational burden (TMB), lactate dehydrogenase (LDH) level, and immunologic factors such as PD-L1 expression, interferon-γ (IFN-γ) gene signature, CD8+ cell infiltration in tumors, and the neutrophil-to-lymphocyte ratio (NLR) [65].